{
    "mainTopic": {
        "title": "Hypersensitivies and autoimmune diseases",
        "content_info": "",
        "subTopics": [
            {
                "title": "Type I",
                "quizzes": [
                    {
                        "question": "What is the principal immunological mechanism that underlies Type I hypersensitivity reactions, often referred to as immediate hypersensitivity?",
                        "goodAnswer": "Type I hypersensitivity is primarily mediated by IgE antibodies, which, upon encountering allergens, cross-link on mast cells and basophils, leading to degranulation and the release of histamine and other inflammatory mediators.",
                        "wrongAnswer_1": "Type I hypersensitivity is primarily mediated by IgG antibodies, which, upon encountering allergens, activate the complement cascade, leading to cell lysis and the release of inflammatory mediators such as leukotrienes and prostaglandins.",
                        "wrongAnswer_2": "Type I hypersensitivity is fundamentally mediated by T cytotoxic lymphocytes, which, upon recognition of allergens presented by MHC class I molecules, directly destroy cells releasing histamine and other preformed mediators.",
                        "wrongAnswer_3": "Type I hypersensitivity is mainly mediated by IgM antibodies, which, upon encountering allergens, form immune complexes that deposit in tissues and activate complement, leading to chronic inflammation and release of cytokines and chemokines.",
                        "wrongAnswer_4": "Type I hypersensitivity is primarily mediated by IgA antibodies, which, upon encountering allergens at mucosal surfaces, activate mast cells and basophils through cross-linking and release of TNF-alpha and other lipid mediators."
                    },
                    {
                        "question": "Identify the crucial cellular event that initiates the immediate inflammatory response in Type I hypersensitivity following the cross-linking of IgE receptors on mast cells by an allergen.",
                        "goodAnswer": "The immediate inflammatory response in Type I hypersensitivity is initiated by the degranulation of mast cells, a process that involves the rapid release of preformed mediators like histamine, tryptase, and chymase from cytoplasmic granules.",
                        "wrongAnswer_1": "The immediate inflammatory response in Type I hypersensitivity is initiated by the activation of the complement cascade, specifically the classical pathway, leading to the generation of anaphylatoxins C3a and C5a, which induce inflammation and vascular permeability.",
                        "wrongAnswer_2": "The immediate inflammatory response in Type I hypersensitivity is initiated by the synthesis and release of prostaglandins and leukotrienes, which are newly generated lipid mediators derived from arachidonic acid metabolism in macrophages and dendritic cells.",
                        "wrongAnswer_3": "The immediate inflammatory response in Type I hypersensitivity is initiated by the apoptosis of mast cells, a programmed cell death mechanism that releases intracellular contents, including cytokines and growth factors, contributing to inflammation and tissue remodeling.",
                        "wrongAnswer_4": "The immediate inflammatory response in Type I hypersensitivity is initiated by the phagocytosis of allergens by mast cells, leading to the activation of intracellular signaling pathways and the subsequent release of reactive oxygen species and lysosomal enzymes."
                    },
                    {
                        "question": "Which of the following is considered a primary preformed mediator released from mast cells during the immediate phase of a Type I hypersensitivity reaction, and what is its principal effect?",
                        "goodAnswer": "Histamine is a primary preformed mediator released from mast cells in Type I hypersensitivity, and its principal effects include vasodilation, increased vascular permeability, and smooth muscle contraction, particularly in the bronchioles.",
                        "wrongAnswer_1": "Interleukin-4 (IL-4) is a primary preformed mediator released from mast cells in Type I hypersensitivity, and its principal effects include the activation of eosinophils, induction of mucus secretion, and stimulation of fibroblast proliferation in the affected tissues.",
                        "wrongAnswer_2": "Tumor Necrosis Factor-alpha (TNF-\u03b1) is a primary preformed mediator released from mast cells in Type I hypersensitivity, and its principal effects include the chemotaxis of neutrophils, activation of endothelial cells, and systemic effects such as fever and acute phase responses.",
                        "wrongAnswer_3": "Prostaglandin D2 (PGD2) is a primary preformed mediator released from mast cells in Type I hypersensitivity, and its principal effects include platelet aggregation, activation of B lymphocytes for antibody production, and stimulation of nerve endings causing pain.",
                        "wrongAnswer_4": "Leukotriene C4 (LTC4) is a primary preformed mediator released from mast cells in Type I hypersensitivity, and its principal effects include the suppression of T cell proliferation, inhibition of macrophage activation, and resolution of inflammation through lipid mediator class switching."
                    }
                ]
            },
            {
                "title": "Type II",
                "quizzes": [
                    {
                        "question": "What is the fundamental immunological mechanism underlying Type II hypersensitivity reactions, also known as antibody-mediated cytotoxic hypersensitivity?",
                        "goodAnswer": "Type II hypersensitivity is fundamentally mediated by IgG and IgM antibodies directed against cell surface or tissue antigens, leading to cellular destruction or functional alteration through complement activation or antibody-dependent cell-mediated cytotoxicity (ADCC).",
                        "wrongAnswer_1": "Type II hypersensitivity is fundamentally mediated by IgE antibodies, which bind to mast cells and basophils, causing degranulation and release of inflammatory mediators upon subsequent exposure to the antigen, leading to immediate hypersensitivity.",
                        "wrongAnswer_2": "Type II hypersensitivity is fundamentally mediated by T helper 1 (Th1) cells, which release cytokines like IFN-\u03b3 and TNF-\u03b1, activating macrophages and inducing granuloma formation and delayed-type hypersensitivity reactions in tissues.",
                        "wrongAnswer_3": "Type II hypersensitivity is fundamentally mediated by immune complex formation involving IgG and IgM antibodies with soluble antigens, leading to complement activation and tissue damage due to deposition in blood vessel walls and glomeruli.",
                        "wrongAnswer_4": "Type II hypersensitivity is fundamentally mediated by T cytotoxic lymphocytes, which directly recognize and kill target cells presenting antigenic peptides via MHC class I molecules, causing tissue destruction and chronic inflammation in affected organs."
                    },
                    {
                        "question": "In the context of Type II hypersensitivity, which effector mechanisms are predominantly involved in the destruction of target cells or tissues coated with antibodies?",
                        "goodAnswer": "Effector mechanisms in Type II hypersensitivity predominantly involve complement activation through the classical pathway, leading to cell lysis via the membrane attack complex (MAC), and antibody-dependent cell-mediated cytotoxicity (ADCC) mediated by NK cells and macrophages.",
                        "wrongAnswer_1": "Effector mechanisms in Type II hypersensitivity predominantly involve the release of preformed mediators from mast cells and basophils, such as histamine and tryptase, leading to vasodilation, increased vascular permeability, and smooth muscle contraction in affected tissues.",
                        "wrongAnswer_2": "Effector mechanisms in Type II hypersensitivity predominantly involve the release of cytokines and chemokines from T helper 2 (Th2) cells, such as IL-4, IL-5, and IL-13, leading to eosinophil activation, mucus production, and airway inflammation.",
                        "wrongAnswer_3": "Effector mechanisms in Type II hypersensitivity predominantly involve the formation of granulomas mediated by macrophages and T helper 1 (Th1) cells, which encapsulate the antigen and cause tissue fibrosis and destruction over time in affected organs.",
                        "wrongAnswer_4": "Effector mechanisms in Type II hypersensitivity predominantly involve the activation of the coagulation cascade and the generation of thrombin, leading to fibrin deposition, microthrombus formation, and ischemic tissue damage in the affected blood vessels."
                    },
                    {
                        "question": "Identify a clinical condition that exemplifies Type II hypersensitivity and describe the pathogenic mechanism involved in this specific disease.",
                        "goodAnswer": "Hemolytic disease of the newborn (erythroblastosis fetalis) exemplifies Type II hypersensitivity, where maternal IgG antibodies against fetal Rh blood group antigens cross the placenta and destroy fetal erythrocytes via complement activation and ADCC.",
                        "wrongAnswer_1": "Systemic lupus erythematosus (SLE) exemplifies Type II hypersensitivity, where autoantibodies against nuclear antigens form immune complexes that deposit in tissues, leading to complement activation and chronic inflammation in multiple organs such as kidneys and joints.",
                        "wrongAnswer_2": "Rheumatoid arthritis (RA) exemplifies Type II hypersensitivity, where T helper 17 (Th17) cells and TNF-alpha play a central role in chronic inflammation and joint destruction, mediated by cytokine release and activation of synovial fibroblasts and chondrocytes.",
                        "wrongAnswer_3": "Allergic asthma exemplifies Type II hypersensitivity, where IgE antibodies against inhaled allergens trigger mast cell degranulation in the airways, leading to bronchoconstriction, mucus production, and airway hyperresponsiveness mediated by histamine and leukotrienes.",
                        "wrongAnswer_4": "Type 1 diabetes mellitus exemplifies Type II hypersensitivity, where autoantibodies and T cytotoxic lymphocytes destroy pancreatic beta cells, leading to insulin deficiency and hyperglycemia mediated by cell-mediated cytotoxicity and cytokine-induced apoptosis."
                    }
                ]
            },
            {
                "title": "Type III",
                "quizzes": [
                    {
                        "question": "What is the fundamental immunological mechanism that characterizes Type III hypersensitivity reactions, also known as immune complex-mediated hypersensitivity?",
                        "goodAnswer": "Type III hypersensitivity is characterized by the formation of immune complexes composed of IgG or IgM antibodies and soluble antigens, which deposit in tissues and blood vessel walls, activating complement and attracting neutrophils, leading to tissue damage.",
                        "wrongAnswer_1": "Type III hypersensitivity is characterized by the activation of mast cells and basophils by IgE antibodies upon re-exposure to allergens, leading to degranulation and the release of histamine and other inflammatory mediators, causing immediate hypersensitivity reactions.",
                        "wrongAnswer_2": "Type III hypersensitivity is characterized by the direct killing of target cells by cytotoxic T lymphocytes (CTLs) that recognize antigenic peptides presented by MHC class I molecules, leading to cellular destruction and chronic inflammation in affected tissues.",
                        "wrongAnswer_3": "Type III hypersensitivity is characterized by the activation of T helper 1 (Th1) cells, which release cytokines like IFN-\u03b3 and TNF-\u03b1, activating macrophages and inducing granuloma formation, leading to delayed-type hypersensitivity reactions in tissues.",
                        "wrongAnswer_4": "Type III hypersensitivity is characterized by the direct binding of IgG or IgM antibodies to cell surface antigens, leading to cell lysis through complement activation or antibody-dependent cell-mediated cytotoxicity (ADCC), causing cytotoxic hypersensitivity reactions."
                    },
                    {
                        "question": "Describe the key steps involved in the pathogenesis of tissue damage in Type III hypersensitivity reactions, starting from immune complex formation.",
                        "goodAnswer": "Pathogenesis of Type III hypersensitivity involves: 1) Immune complex formation -> 2) Deposition of complexes in tissues/vessels -> 3) Complement activation (classical pathway) -> 4) Neutrophil chemotaxis and activation -> 5) Release of lysosomal enzymes and inflammatory mediators -> 6) Tissue damage and inflammation.",
                        "wrongAnswer_1": "Pathogenesis of Type III hypersensitivity involves: 1) Antigen presentation by APCs -> 2) Activation of T helper 1 (Th1) cells -> 3) Release of IFN-\u03b3 and TNF-\u03b1 -> 4) Macrophage activation and granuloma formation -> 5) Chronic inflammation and tissue fibrosis -> 6) Tissue remodeling and functional impairment.",
                        "wrongAnswer_2": "Pathogenesis of Type III hypersensitivity involves: 1) Allergen exposure -> 2) IgE antibody production -> 3) IgE binding to mast cells -> 4) Allergen cross-linking of IgE on mast cells -> 5) Mast cell degranulation and histamine release -> 6) Immediate hypersensitivity symptoms.",
                        "wrongAnswer_3": "Pathogenesis of Type III hypersensitivity involves: 1) Autoantibody production (IgG/IgM) -> 2) Antibody binding to cell surface antigens -> 3) Complement activation (classical pathway) -> 4) Cell lysis via MAC or ADCC -> 5) Tissue destruction and inflammation -> 6) Organ dysfunction.",
                        "wrongAnswer_4": "Pathogenesis of Type III hypersensitivity involves: 1) Activation of T cytotoxic lymphocytes (CTLs) -> 2) Recognition of viral antigens on infected cells -> 3) CTL-mediated killing of infected cells -> 4) Release of perforin and granzymes -> 5) Tissue necrosis and inflammation -> 6) Resolution of infection or chronic disease."
                    },
                    {
                        "question": "Identify a clinical condition that is a classic example of Type III hypersensitivity reaction and explain the underlying immune complex-mediated pathology in this condition.",
                        "goodAnswer": "Serum sickness is a classic example of Type III hypersensitivity, where administration of foreign serum proteins leads to the formation of immune complexes, which deposit in tissues like joints, kidneys, and blood vessels, causing fever, rash, arthritis, and glomerulonephritis due to complement activation and inflammation.",
                        "wrongAnswer_1": "Contact dermatitis is a classic example of Type III hypersensitivity, where skin exposure to haptens like poison ivy leads to the activation of T helper 1 (Th1) cells, which release cytokines and chemokines, causing a localized inflammatory skin reaction characterized by erythema, edema, and vesicles due to cell-mediated cytotoxicity.",
                        "wrongAnswer_2": "Anaphylaxis is a classic example of Type III hypersensitivity, where systemic exposure to allergens in sensitized individuals leads to rapid mast cell degranulation and release of histamine and other mediators, causing widespread vasodilation, bronchoconstriction, and potentially life-threatening circulatory shock due to IgE-mediated immediate hypersensitivity.",
                        "wrongAnswer_3": "Autoimmune hemolytic anemia is a classic example of Type III hypersensitivity, where autoantibodies against red blood cell antigens lead to erythrocyte destruction via complement activation and antibody-dependent cell-mediated cytotoxicity (ADCC), causing anemia and jaundice due to antibody-mediated cytotoxicity.",
                        "wrongAnswer_4": "Graft-versus-host disease (GVHD) is a classic example of Type III hypersensitivity, where donor T cells in transplanted bone marrow or organs recognize recipient tissues as foreign, leading to T cell activation, cytokine release, and tissue damage in skin, liver, and gut due to cell-mediated cytotoxicity and delayed-type hypersensitivity."
                    }
                ]
            },
            {
                "title": "Type IV",
                "quizzes": [
                    {
                        "question": "What is the principal immunological mechanism that underlies Type IV hypersensitivity reactions, also known as delayed-type hypersensitivity (DTH) or cell-mediated hypersensitivity?",
                        "goodAnswer": "Type IV hypersensitivity is primarily mediated by T cells, specifically CD4+ Th1 cells and CD8+ cytotoxic T lymphocytes (CTLs), which, upon encountering antigens, release cytokines (Th1) or directly kill target cells (CTLs), leading to inflammation and tissue damage that develops over 24-72 hours.",
                        "wrongAnswer_1": "Type IV hypersensitivity is primarily mediated by IgE antibodies, which, upon encountering allergens, cross-link on mast cells and basophils, leading to degranulation and the immediate release of histamine and other inflammatory mediators, causing rapid onset allergic reactions.",
                        "wrongAnswer_2": "Type IV hypersensitivity is primarily mediated by IgG and IgM antibodies directed against cell surface antigens, leading to cell lysis or functional alteration through complement activation or antibody-dependent cell-mediated cytotoxicity (ADCC), causing cytotoxic hypersensitivity reactions.",
                        "wrongAnswer_3": "Type IV hypersensitivity is primarily mediated by immune complex formation involving IgG and IgM antibodies with soluble antigens, which deposit in tissues and activate complement, leading to neutrophil chemotaxis and tissue damage, causing immune complex-mediated hypersensitivity reactions.",
                        "wrongAnswer_4": "Type IV hypersensitivity is primarily mediated by B cells, which, upon encountering antigens, differentiate into plasma cells and produce large quantities of antibodies, leading to humoral immunity and protection against extracellular pathogens through neutralization and opsonization mechanisms."
                    },
                    {
                        "question": "Describe the sequence of cellular events in a typical Type IV hypersensitivity reaction, starting from antigen presentation to the development of clinical manifestations.",
                        "goodAnswer": "Type IV hypersensitivity sequence: 1) Antigen processing and presentation by APCs -> 2) Activation of sensitized T cells (Th1 or CTLs) -> 3) Release of cytokines (Th1) or CTL-mediated cytotoxicity -> 4) Recruitment of macrophages and inflammatory cells -> 5) Granuloma formation or tissue destruction -> 6) Clinical manifestations (erythema, induration, tissue damage).",
                        "wrongAnswer_1": "Type IV hypersensitivity sequence: 1) Allergen exposure -> 2) IgE antibody production -> 3) IgE binding to mast cells -> 4) Allergen cross-linking of IgE -> 5) Mast cell degranulation and histamine release -> 6) Immediate hypersensitivity symptoms (wheal and flare, bronchoconstriction).",
                        "wrongAnswer_2": "Type IV hypersensitivity sequence: 1) Antibody production (IgG/IgM) -> 2) Antibody binding to cell surface antigens -> 3) Complement activation (classical pathway) -> 4) Cell lysis via MAC or ADCC -> 5) Tissue inflammation and destruction -> 6) Organ dysfunction and clinical signs.",
                        "wrongAnswer_3": "Type IV hypersensitivity sequence: 1) Immune complex formation -> 2) Deposition in tissues and blood vessels -> 3) Complement activation (classical pathway) -> 4) Neutrophil chemotaxis and activation -> 5) Release of lysosomal enzymes and mediators -> 6) Tissue damage and systemic inflammation.",
                        "wrongAnswer_4": "Type IV hypersensitivity sequence: 1) B cell activation and differentiation -> 2) Plasma cell antibody production (IgA/IgM) -> 3) Antibody neutralization of pathogens in mucosa or blood -> 4) Opsonization and phagocytosis of pathogens -> 5) Clearance of infection and resolution of inflammation -> 6) Protective immunity development."
                    },
                    {
                        "question": "Identify a clinical condition that exemplifies Type IV hypersensitivity and explain the cellular and molecular mechanisms involved in its pathogenesis.",
                        "goodAnswer": "Contact dermatitis (e.g., poison ivy) exemplifies Type IV hypersensitivity, where haptens penetrate the skin, are processed by Langerhans cells (APCs), presented to sensitized Th1 cells, leading to release of cytokines like IFN-\u03b3 and TNF-\u03b1, macrophage activation, and localized skin inflammation with erythema, vesicles, and pruritus.",
                        "wrongAnswer_1": "Systemic anaphylaxis (e.g., bee sting allergy) exemplifies Type IV hypersensitivity, where systemic allergen exposure in sensitized individuals triggers rapid mast cell degranulation and release of histamine, causing widespread vasodilation, bronchoconstriction, and circulatory shock due to IgE-mediated immediate hypersensitivity.",
                        "wrongAnswer_2": "Autoimmune hemolytic anemia exemplifies Type IV hypersensitivity, where autoantibodies against red blood cell antigens lead to erythrocyte destruction via complement activation and antibody-dependent cell-mediated cytotoxicity (ADCC), causing anemia and jaundice due to antibody-mediated cytotoxicity.",
                        "wrongAnswer_3": "Serum sickness exemplifies Type IV hypersensitivity, where administration of foreign serum proteins leads to the formation of immune complexes, which deposit in tissues like joints and kidneys, causing fever, rash, arthritis, and glomerulonephritis due to complement activation and inflammation in immune complex-mediated disease.",
                        "wrongAnswer_4": "Rheumatoid arthritis exemplifies Type IV hypersensitivity, where autoantibodies against IgG (rheumatoid factor) and citrullinated proteins form immune complexes in joints, leading to chronic inflammation, synovial hyperplasia, and joint destruction due to immune complex deposition and complement activation in the synovium."
                    }
                ]
            },
            {
                "title": "Allergy and atopy",
                "quizzes": [
                    {
                        "question": "Define 'allergy' in immunological terms and distinguish it from other types of hypersensitivity reactions based on its underlying mechanism.",
                        "goodAnswer": "Allergy is defined as a Type I hypersensitivity reaction characterized by an exaggerated immune response mediated by IgE antibodies to typically harmless environmental antigens (allergens), leading to mast cell degranulation and release of inflammatory mediators upon subsequent exposure.",
                        "wrongAnswer_1": "Allergy is defined as a Type II hypersensitivity reaction characterized by antibody-mediated cytotoxicity where IgG or IgM antibodies target cell surface antigens, leading to cell destruction through complement activation or ADCC, causing tissue damage and organ dysfunction.",
                        "wrongAnswer_2": "Allergy is defined as a Type III hypersensitivity reaction characterized by immune complex formation and deposition in tissues, leading to complement activation and neutrophil-mediated inflammation, resulting in systemic or localized tissue injury and vascular damage.",
                        "wrongAnswer_3": "Allergy is defined as a Type IV hypersensitivity reaction characterized by T cell-mediated delayed-type hypersensitivity, where sensitized T cells release cytokines or directly kill target cells upon antigen encounter, leading to chronic inflammation and tissue destruction.",
                        "wrongAnswer_4": "Allergy is defined as a Type V hypersensitivity reaction characterized by stimulatory autoantibodies that bind to cell surface receptors and mimic the action of natural ligands, leading to hyperfunction of the target cell and associated physiological disturbances."
                    },
                    {
                        "question": "What is 'atopy', and how does it relate to allergy in terms of predisposition and clinical manifestations?",
                        "goodAnswer": "Atopy is a genetic predisposition to produce excessive IgE antibodies in response to common environmental allergens, predisposing individuals to develop allergic diseases like allergic rhinitis, asthma, and eczema. Atopy is a key risk factor for developing allergies.",
                        "wrongAnswer_1": "Atopy is a condition characterized by the presence of autoantibodies against self-antigens, leading to autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus. Atopy is a major determinant of autoimmune disease susceptibility.",
                        "wrongAnswer_2": "Atopy is a state of immune deficiency characterized by impaired T cell function, predisposing individuals to opportunistic infections and malignancies. Atopy is a primary cause of immunodeficiency syndromes and increased cancer risk.",
                        "wrongAnswer_3": "Atopy is a condition characterized by chronic inflammation in tissues due to persistent infections or exposure to irritants, leading to tissue remodeling and fibrosis. Atopy is a consequence of chronic inflammatory conditions and environmental exposures.",
                        "wrongAnswer_4": "Atopy is a protective immune response characterized by enhanced cell-mediated immunity against intracellular pathogens, leading to increased resistance to viral and bacterial infections. Atopy is a beneficial immune mechanism that enhances host defense against infections."
                    },
                    {
                        "question": "Describe the role of specific cytokines, such as IL-4 and IL-13, in the development and maintenance of atopic conditions and allergic responses.",
                        "goodAnswer": "IL-4 and IL-13, produced by Th2 cells and other immune cells, are crucial in atopy and allergy by promoting IgE class switching in B cells, enhancing mast cell and basophil differentiation, and inducing mucus production and airway hyperresponsiveness, thus driving allergic inflammation.",
                        "wrongAnswer_1": "IL-12 and IFN-\u03b3, produced by Th1 cells and NK cells, are crucial in atopy and allergy by promoting IgG class switching in B cells, enhancing macrophage activation, and suppressing IgE production, thus resolving allergic inflammation and promoting immune tolerance.",
                        "wrongAnswer_2": "TGF-\u03b2 and IL-10, produced by regulatory T cells (Tregs), are crucial in atopy and allergy by promoting IgA class switching in B cells, enhancing epithelial barrier function, and suppressing Th2 responses, thus preventing allergic sensitization and maintaining immune homeostasis.",
                        "wrongAnswer_3": "TNF-\u03b1 and IL-1\u03b2, produced by macrophages and dendritic cells, are crucial in atopy and allergy by promoting neutrophil chemotaxis, inducing acute phase responses, and enhancing vascular permeability, thus driving inflammatory responses in both allergic and non-allergic conditions.",
                        "wrongAnswer_4": "IL-17 and IL-22, produced by Th17 cells, are crucial in atopy and allergy by promoting antimicrobial peptide production, enhancing epithelial cell proliferation, and driving neutrophilic inflammation, thus contributing to tissue remodeling and chronic inflammatory diseases independent of allergy."
                    }
                ]
            },
            {
                "title": "Asthma",
                "quizzes": [
                    {
                        "question": "Define asthma as a chronic respiratory disease and describe its key pathological features in the context of airway inflammation and hyperresponsiveness.",
                        "goodAnswer": "Asthma is a chronic inflammatory disease of the airways characterized by reversible airflow obstruction, bronchial hyperresponsiveness, and underlying inflammation involving eosinophils, mast cells, Th2 lymphocytes, and structural changes like airway remodeling and mucus hypersecretion.",
                        "wrongAnswer_1": "Asthma is a chronic infectious disease of the airways characterized by irreversible airflow obstruction, alveolar destruction, and underlying inflammation primarily involving neutrophils, macrophages, and proteolytic enzymes, leading to emphysema and chronic bronchitis-like symptoms.",
                        "wrongAnswer_2": "Asthma is a chronic neoplastic disease of the airways characterized by uncontrolled proliferation of bronchial epithelial cells, leading to airway obstruction, atelectasis, and underlying inflammation involving tumor-associated macrophages and cytotoxic T lymphocytes, resembling lung cancer.",
                        "wrongAnswer_3": "Asthma is a chronic fibrotic disease of the lung parenchyma characterized by irreversible airflow obstruction, interstitial fibrosis, and underlying inflammation involving fibroblasts, myofibroblasts, and collagen deposition, leading to restrictive lung disease and impaired gas exchange.",
                        "wrongAnswer_4": "Asthma is a chronic vascular disease of the pulmonary circulation characterized by irreversible airflow obstruction, pulmonary hypertension, and underlying inflammation involving endothelial cells, smooth muscle cells, and thrombus formation, leading to right heart failure and pulmonary embolism-like symptoms."
                    },
                    {
                        "question": "Outline the major immunological mechanisms contributing to the pathogenesis of allergic asthma, emphasizing the roles of IgE, mast cells, Th2 cells, and eosinophils.",
                        "goodAnswer": "Pathogenesis of allergic asthma involves: 1) Allergen sensitization and IgE production -> 2) IgE binding to mast cells in airways -> 3) Allergen re-exposure and mast cell degranulation -> 4) Release of histamine, leukotrienes, PGD2 -> 5) Th2 cell activation and cytokine release (IL-4, IL-5, IL-13) -> 6) Eosinophil recruitment and activation -> 7) Airway inflammation, hyperresponsiveness, and remodeling.",
                        "wrongAnswer_1": "Pathogenesis of allergic asthma involves: 1) Viral infection of respiratory epithelium -> 2) Activation of cytotoxic T lymphocytes (CTLs) -> 3) CTL-mediated killing of infected cells -> 4) Release of perforin and granzymes -> 5) Neutrophil recruitment and activation -> 6) Tissue necrosis and inflammation -> 7) Airway destruction and irreversible obstruction.",
                        "wrongAnswer_2": "Pathogenesis of allergic asthma involves: 1) Autoantibody production against lung antigens -> 2) Immune complex formation and deposition in airways -> 3) Complement activation (classical pathway) -> 4) Neutrophil chemotaxis and activation -> 5) Release of lysosomal enzymes and mediators -> 6) Tissue damage and inflammation -> 7) Chronic airway fibrosis and remodeling.",
                        "wrongAnswer_3": "Pathogenesis of allergic asthma involves: 1) Activation of T regulatory cells (Tregs) -> 2) Release of TGF-\u03b2 and IL-10 -> 3) Suppression of Th2 responses and IgE production -> 4) Inhibition of mast cell and eosinophil activation -> 5) Resolution of airway inflammation and hyperresponsiveness -> 6) Immune tolerance and disease remission.",
                        "wrongAnswer_4": "Pathogenesis of allergic asthma involves: 1) Activation of B cells and IgG production -> 2) IgG binding to allergens in airways -> 3) Antibody-dependent cell-mediated cytotoxicity (ADCC) by NK cells -> 4) Release of cytotoxic granules and mediators -> 5) Macrophage activation and phagocytosis -> 6) Clearance of allergens and resolution of inflammation -> 7) Acquired immunity and disease prevention."
                    },
                    {
                        "question": "Describe the roles of specific inflammatory mediators, such as histamine, leukotrienes, and cytokines (e.g., IL-5, IL-13), in the acute and chronic phases of asthma pathogenesis.",
                        "goodAnswer": "In asthma, histamine (acute) causes bronchoconstriction, vascular permeability; Leukotrienes (acute/chronic) induce bronchoconstriction, mucus secretion, eosinophil chemotaxis; IL-5 (chronic) promotes eosinophil maturation and activation; IL-13 (chronic) induces mucus production, IgE class switching, and airway remodeling.",
                        "wrongAnswer_1": "In asthma, TNF-\u03b1 (acute) causes bronchodilation, decreased vascular permeability; Prostaglandins (acute/chronic) inhibit bronchoconstriction, suppress mucus secretion, and inhibit eosinophil chemotaxis; IL-12 (chronic) promotes macrophage activation and Th1 responses; IFN-\u03b3 (chronic) inhibits IgE production and airway remodeling.",
                        "wrongAnswer_2": "In asthma, Bradykinin (acute) causes vasoconstriction, increased vascular permeability; Thromboxanes (acute/chronic) induce platelet aggregation, inhibit mucus secretion, and promote neutrophil chemotaxis; IL-10 (chronic) promotes regulatory T cell function and suppresses inflammation; TGF-\u03b2 (chronic) inhibits fibrosis and airway remodeling.",
                        "wrongAnswer_3": "In asthma, Serotonin (acute) causes bronchodilation, decreased mucus secretion; Lipoxins (acute/chronic) resolve inflammation, inhibit bronchoconstriction, and suppress eosinophil activation; IL-6 (chronic) promotes acute phase responses and systemic inflammation; IL-17 (chronic) induces neutrophilic inflammation and airway remodeling.",
                        "wrongAnswer_4": "In asthma, Nitric oxide (acute) causes bronchodilation, decreased vascular permeability; Resolvins (acute/chronic) promote resolution of inflammation, inhibit mucus production, and suppress mast cell degranulation; IL-2 (chronic) promotes T cell proliferation and activation; IL-4 (chronic) inhibits eosinophil differentiation and mucus production."
                    }
                ]
            },
            {
                "title": "Autoimmune diseases - Type I diabetes",
                "quizzes": [
                    {
                        "question": "Define autoimmune diseases and explain the fundamental immunological mechanisms that lead to the breakdown of self-tolerance and subsequent autoimmune reactions, focusing on Type 1 diabetes mellitus (T1DM).",
                        "goodAnswer": "Autoimmune diseases arise from a breakdown of self-tolerance, where the immune system mistakenly targets and destroys self-tissues. In T1DM, this involves autoimmune destruction of pancreatic beta cells by T cells and autoantibodies, leading to insulin deficiency and hyperglycemia.",
                        "wrongAnswer_1": "Autoimmune diseases arise from an exaggerated immune response to harmless environmental antigens, leading to allergic reactions and tissue inflammation. In T1DM, this involves IgE-mediated mast cell degranulation in the pancreas, causing acute pancreatitis and insulin resistance.",
                        "wrongAnswer_2": "Autoimmune diseases arise from chronic infections by intracellular pathogens, leading to persistent immune activation and bystander tissue damage. In T1DM, this involves viral infection of pancreatic beta cells, triggering chronic inflammation and insulin deficiency due to viral cytopathic effects.",
                        "wrongAnswer_3": "Autoimmune diseases arise from genetic defects in complement components, leading to impaired clearance of immune complexes and chronic inflammation. In T1DM, this involves complement-mediated destruction of pancreatic beta cells due to immune complex deposition and neutrophil infiltration.",
                        "wrongAnswer_4": "Autoimmune diseases arise from metabolic disorders and accumulation of toxic metabolites, leading to cellular stress and tissue damage. In T1DM, this involves glucose toxicity in pancreatic beta cells, causing cellular dysfunction and apoptosis, ultimately leading to insulin deficiency and hyperglycemia."
                    },
                    {
                        "question": "Describe the key cellular and molecular players involved in the autoimmune destruction of pancreatic beta cells in Type 1 diabetes mellitus (T1DM), including T cells, autoantibodies, and cytokines.",
                        "goodAnswer": "In T1DM, key players are: 1) CD4+ Th1 cells and CD8+ CTLs, which infiltrate islets and mediate beta cell destruction via cytokines (IFN-\u03b3, TNF-\u03b1) and cytotoxicity; 2) Autoantibodies (anti-GAD, anti-insulin, anti-IA-2), which contribute to beta cell destruction via ADCC and complement activation; 3) Pro-inflammatory cytokines (IL-1\u03b2, TNF-\u03b1) from macrophages, amplifying inflammation.",
                        "wrongAnswer_1": "In T1DM, key players are: 1) CD4+ Th2 cells, which promote beta cell regeneration and insulin production via cytokines (IL-4, IL-13); 2) IgE antibodies, which protect beta cells from autoimmune attack by blocking T cell recognition and inhibiting inflammatory responses; 3) Anti-inflammatory cytokines (IL-10, TGF-\u03b2) from regulatory T cells (Tregs), resolving islet inflammation and promoting immune tolerance.",
                        "wrongAnswer_2": "In T1DM, key players are: 1) B cells, which produce neutralizing antibodies against viral antigens on beta cells, preventing viral infection and preserving beta cell function; 2) IgM antibodies, which activate complement and promote beta cell survival by enhancing glucose uptake and insulin secretion; 3) Growth factors (IGF-1, VEGF) from stromal cells, stimulating beta cell proliferation and angiogenesis in pancreatic islets.",
                        "wrongAnswer_3": "In T1DM, key players are: 1) Neutrophils, which phagocytose dead beta cells and clear cellular debris, preventing chronic inflammation and promoting tissue repair; 2) Complement components, which opsonize beta cells for phagocytosis and enhance immune complex clearance, reducing autoimmune damage; 3) Anti-apoptotic factors (Bcl-2, Bcl-xL) in beta cells, promoting cell survival and resistance to autoimmune attack.",
                        "wrongAnswer_4": "In T1DM, key players are: 1) NK cells, which mediate antibody-dependent cell-mediated cytotoxicity (ADCC) of beta cells coated with autoantibodies, directly killing target cells; 2) IgA antibodies, which neutralize autoantigens in pancreatic ducts and prevent systemic immune activation, reducing autoimmune inflammation; 3) Pro-resolving lipid mediators (resolvins, lipoxins) from macrophages, actively resolving inflammation and promoting tissue homeostasis."
                    },
                    {
                        "question": "Describe the genetic and environmental risk factors that contribute to the development of Type 1 diabetes mellitus (T1DM), highlighting the major HLA associations and potential environmental triggers.",
                        "goodAnswer": "T1DM risk factors include: 1) Genetic predisposition: HLA genes (DR3, DR4, DQ2, DQ8) account for ~50% heritability, influencing antigen presentation and T cell activation; 2) Environmental triggers: Viral infections (coxsackievirus, rubella), dietary factors (cow's milk proteins), and gut microbiome dysbiosis may initiate or accelerate autoimmunity in susceptible individuals.",
                        "wrongAnswer_1": "T1DM risk factors include: 1) Genetic predisposition: Genes encoding complement components (C3, C4) account for ~50% heritability, influencing immune complex clearance and chronic inflammation; 2) Environmental triggers: Bacterial infections (streptococcus, staphylococcus), air pollution, and heavy metal exposure may initiate or accelerate autoimmunity by inducing systemic inflammation and tissue damage.",
                        "wrongAnswer_2": "T1DM risk factors include: 1) Genetic predisposition: Genes encoding cytokine receptors (IL-2R, TNF-R) account for ~50% heritability, influencing inflammatory responses and immune regulation; 2) Environmental triggers: Fungal infections (candida, aspergillus), radiation exposure, and cigarette smoking may initiate or accelerate autoimmunity by disrupting immune homeostasis and promoting oxidative stress.",
                        "wrongAnswer_3": "T1DM risk factors include: 1) Genetic predisposition: Genes encoding pattern recognition receptors (TLRs, NLRs) account for ~50% heritability, influencing innate immune activation and inflammatory responses; 2) Environmental triggers: Parasitic infections (helminths, protozoa), stress, and sleep deprivation may initiate or accelerate autoimmunity by altering immune cell function and promoting immune dysregulation.",
                        "wrongAnswer_4": "T1DM risk factors include: 1) Genetic predisposition: Genes encoding adhesion molecules (ICAM-1, VCAM-1) account for ~50% heritability, influencing leukocyte trafficking and tissue infiltration; 2) Environmental triggers: Allergen exposure (pollen, dust mites), physical trauma, and hormonal imbalances may initiate or accelerate autoimmunity by inducing tissue injury and promoting self-antigen release."
                    }
                ]
            }
        ],
        "team_name": "Bob\u00f3kocka"
    }
}
